Permanent Pacemaker Reduction Using Cusp-Overlapping Projection in TAVR: A Propensity Score Analysis.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
24 01 2022
Historique:
received: 09 06 2021
revised: 27 09 2021
accepted: 05 10 2021
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 31 3 2022
Statut: ppublish

Résumé

The aim of this study was to determine if modifying the classical implantation technique for self-expanding (SE) transcatheter aortic valve replacement to a novel cusp-overlapping projection (COP) technique results in a higher implantation depth (ID) and subsequently reduces the rate of permanent pacemaker implantation (PPMI). The COP technique presents the potential benefit of an optimized ID to reduce the rate of PPMI. However, only a few studies have compared clinical outcomes with those achieved using the standard technique. This is the first study to systematically evaluate this approach for SE transcatheter heart valves (THVs) in different populations METHODS: Beginning in February 2015, 444 patients were consecutively included. Propensity score matching was used to control baseline characteristics because of the observational nature of the study. In total, 161 pairs of patients were analyzed. Three methods were used to measure ID (noncoronary cusp [NCC] to the THV, mean of the NCC and the left coronary cusp [LCC] to the THV, and the deepest edge from the LCC and the NCC to the THV). ID was significantly higher in COP cases when measuring from the NCC (4.2 mm vs 5.3 mm; P < 0.001) and the mean from the NCC and the LCC (5.3 mm vs 5.9 mm; P = 0.04), but not from the deepest edge. The PPMI rate was lower in the COP group: 19 (11.8%) vs 35 (21.7%) (P = 0.03; relative risk: 0.54; 95% CI: 0.32-0.91). The present study showed that the COP technique significantly reduces PPMI in SE THV implantation compared with the classical implantation technique, with similar rates of complications.

Sections du résumé

OBJECTIVES
The aim of this study was to determine if modifying the classical implantation technique for self-expanding (SE) transcatheter aortic valve replacement to a novel cusp-overlapping projection (COP) technique results in a higher implantation depth (ID) and subsequently reduces the rate of permanent pacemaker implantation (PPMI).
BACKGROUND
The COP technique presents the potential benefit of an optimized ID to reduce the rate of PPMI. However, only a few studies have compared clinical outcomes with those achieved using the standard technique. This is the first study to systematically evaluate this approach for SE transcatheter heart valves (THVs) in different populations METHODS: Beginning in February 2015, 444 patients were consecutively included. Propensity score matching was used to control baseline characteristics because of the observational nature of the study. In total, 161 pairs of patients were analyzed. Three methods were used to measure ID (noncoronary cusp [NCC] to the THV, mean of the NCC and the left coronary cusp [LCC] to the THV, and the deepest edge from the LCC and the NCC to the THV).
RESULTS
ID was significantly higher in COP cases when measuring from the NCC (4.2 mm vs 5.3 mm; P < 0.001) and the mean from the NCC and the LCC (5.3 mm vs 5.9 mm; P = 0.04), but not from the deepest edge. The PPMI rate was lower in the COP group: 19 (11.8%) vs 35 (21.7%) (P = 0.03; relative risk: 0.54; 95% CI: 0.32-0.91).
CONCLUSIONS
The present study showed that the COP technique significantly reduces PPMI in SE THV implantation compared with the classical implantation technique, with similar rates of complications.

Identifiants

pubmed: 35057985
pii: S1936-8798(21)01832-X
doi: 10.1016/j.jcin.2021.10.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

150-161

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Dr Moris is a proctor for Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Isaac Pascual (I)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain; Department of Medicine, Faculty of Medicine, University of Oviedo, Oviedo, Spain.

Daniel Hernández-Vaquero (D)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain; Department of Medicine, Faculty of Medicine, University of Oviedo, Oviedo, Spain.

Alberto Alperi (A)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Marcel Almendarez (M)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain.

Pablo Avanzas (P)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain; Department of Medicine, Faculty of Medicine, University of Oviedo, Oviedo, Spain. Electronic address: avanzas@secardiologia.es.

Dimitri Kalavrouziotis (D)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Rebeca Lorca (R)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain.

Jules Mesnier (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Luis Arboine (L)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Interventional Cardiology Department, Unidad Médica de Alta Especialidad, Hospital de Cardiología 34, Monterrey, Mexico.

Siamak Mohammadi (S)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Raquel Del Valle (RD)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain.

Eric Dumont (E)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Victor Leon (V)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain.

Robert De Larochelliere (R)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada.

Cesar Moris (C)

Heart Area, Hospital Universitario Central de Asturias, Oviedo, Spain; Research Institute of the Principado de Asturias, Oviedo, Spain; Department of Medicine, Faculty of Medicine, University of Oviedo, Oviedo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH